NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan

Not Yet RecruitingN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Metastatic Prostate Cancer

The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer

Eligibility overview

Sex: MALE

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion criteria:

Age ≥ 18 years at index date

* Diagnosis of mPC
* PSMA positive
* Received at least one dose of lutetium (177Lu) vipivotide tetraxetan on or after mPC diagnosis date

Exclusion criterion:

• Current or prior participation in an investigational study within the 30-day period immediately prior to and including the index date, or within five half-lives of the investigational product (whichever is longer)